Zotiraciclib (TG02) Plus Dose-Dense or Metronomic Temozolomide Followed by Randomized Phase II Trial of Zotiraciclib (TG02) Plus Temozolomide Versus Temozolomide Alone in Adults With Recurrent Anaplastic Astrocytoma and Glioblastoma
Clinical trial NCT02942264 · TERMINATED
Trial details
- NCT number
- NCT02942264
- Sponsor
- National Cancer Institute (NCI)
- Status
- TERMINATED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2016-12-14
- Primary completion
- 2020-08-26
- Enrollment
- 53
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.